Organicell Regenerative Medicine's Zofin nabs accelerated review in U.S. to treat COVID-19 patients

Stock Information for Organicell Regenerative Medicine Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Organicell Regenerative Medicine Inc

ZEO ScientifiX and Exotropin Join Forces to Launch a Solution to Address the Growing Unmet Need for Hair Loss
ZEO ScientifiX, a Leading South Florida Biotechnology Company, Launches Regenerative Medicine Educational Series for Physicians
ZEO ScientifiX Partners with National Provider of Healthcare Services
ZEO ScientifiX is Moving Toward Its Goal of Transforming Healthcare Through Leading-Edge Research
RETRANSMISSION: Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
Organicell Announces 1-for-200 Reverse Stock Split
Organicell Reports Interim Results of Phase 1/2A Research Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.